Emerging treatments for postmenopausal osteoporosis – focus on denosumab

References

• SeemanEBone quality – the material and structural basis of bone strength and fragilityN Engl J Med2006354212250226116723616
   PubMed Web of Science ®Google Scholar
• KearnsAEReceptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and diseaseEndocr Rev200829215519218057140
   PubMed Web of Science ®Google Scholar
• HattnerRSuggested sequential mode of control of changes in cell behaviour in adult bone remodellingNature19652069834894905319106
   PubMed Web of Science ®Google Scholar
• ParfittAMQuantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosisCalcif Tissue Int197924;28115115547
   PubMed Web of Science ®Google Scholar
• SimonetWSOsteoprotegerin: a novel secreted protein involved in the regulation of bone densityCell19978923093199108485
   PubMed Web of Science ®Google Scholar
• LaceyDLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell19989321651769568710
   PubMed Web of Science ®Google Scholar
• BucayNOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationGenes Dev1998129126012689573043
   PubMed Web of Science ®Google Scholar
• RodanGARole of osteoblasts in hormonal control of bone resorption: a hypothesisCalcif Tissue Int1981333493516271355
   PubMed Web of Science ®Google Scholar
• LaceyDLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell1998931651769568710
   PubMed Web of Science ®Google Scholar
• YasudaHOsteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProc Natl Acad Sci U S A1998957359736029520411
   PubMed Web of Science ®Google Scholar
• WongBTRANCE (tumor necrosis factor [TNF]-related activation induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factorJ Exp Med1997186207520809396779
   PubMed Web of Science ®Google Scholar
• GlassDACanonical wnt signaling in differentiated osteoblasts controls osteoclast differentiationDev Cell2005875176415866165
   PubMed Web of Science ®Google Scholar
• TatsumiSTargeted ablation of osteocytes induces osteoporosis with defective mechanotransductionCell Metab2007546447517550781
   PubMed Web of Science ®Google Scholar
• GoldringSREating bone or adding it: the Wnt pathway decidesNat Med200713213313417290270
   PubMed Web of Science ®Google Scholar
• BurgessTThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclastsJ Cell Biol19994552753
   Web of Science ®Google Scholar
• AkatsuTOsteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancyBone1998234954989855457
   PubMed Web of Science ®Google Scholar
• TeitelbaumSLGenetic regulation of osteoclast development and functionNat Rev Genet2003486384912897775
   PubMed Web of Science ®Google Scholar
• CleutjensKBNoninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profilingJ Clin Invest200811882979298518654662
   PubMed Web of Science ®Google Scholar
• HughesAEMutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysisNat Genet2000241454810615125
   PubMed Web of Science ®Google Scholar
• SchettGThe role of osteoprotegerin in arthritisArthritis Res Ther20035523924512932284
   PubMed Web of Science ®Google Scholar
• PettitARRANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritisRheumatology (Oxford)20064591068107616490750
   PubMed Web of Science ®Google Scholar
• GravalleseEMIdentification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritisAm J Pathol199815249439519546355
   PubMed Web of Science ®Google Scholar
• GoldringSRBone and joint destruction in rheumatoid arthritis: what is really happeningJ Rheumatol Suppl2002654448 Erratum in: J Rheumatol Suppl. 2002;29(11):2471.12236623
   PubMedGoogle Scholar
• PagetSThe distribution of secondary growths in cancer of the breastLancet18891571573
   Google Scholar
• SchwarzEMClinical development of anti-RANKL therapyArthritis Res Ther20079Suppl 1S7
   PubMed Web of Science ®Google Scholar
• BerensonJRAdvances in the biology and treatment of myeloma bone diseaseSemin Oncol200229111612520479
   PubMed Web of Science ®Google Scholar
• BekkerPJThe effect of a single dose of osteoprotegerin in post-menopausal womenJ Bone Miner Res200116234836011204435
   PubMed Web of Science ®Google Scholar
• BekkerPJA single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal womenJ Bone Miner Res20041971059106615176987
   PubMed Web of Science ®Google Scholar
• McClungMRDenosumab in post-menopausal women with low bone mineral densityN Engl J Med200635482183116495394
   PubMed Web of Science ®Google Scholar
• LewieckiEMAMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMDJ Bone Miner Res200722121832184117708711
   PubMed Web of Science ®Google Scholar
• BeckTJEffects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronateJ Clin Densitom200811335135918495508
   PubMed Web of Science ®Google Scholar
• MillerPDAmg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trialBone200843222222918539106
   PubMed Web of Science ®Google Scholar
• BrownJPComparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJ Bone Miner Res200924115316118767928
   PubMed Web of Science ®Google Scholar
• BoneHGEffects of denosumab on bone mineral density and bone turnover in postmenopausal womenJ Clin Endocrinol Metab20089362149215718381571
   PubMed Web of Science ®Google Scholar
• CummingsSRA phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM TrialASBMR meeting, Montreal, 2008; Abstract 1286.
   Google Scholar
• GeusensPPThe ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destructionArthritis Rheum20065461772177716736519
   PubMed Web of Science ®Google Scholar
• CohenSBDenosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trialArthritis Rheum20085851299130918438830
   PubMed Web of Science ®Google Scholar
• BodyJJA study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerClin Cancer Res200615;1241221122816489077
   PubMed Web of Science ®Google Scholar
• LiptonARandomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesJ Clin Oncol200725284431443717785705
   PubMed Web of Science ®Google Scholar
• EllisGKRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
   PubMed Web of Science ®Google Scholar
• LiptonAExtended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapyClin Cancer Res200814206690669618927312
   PubMed Web of Science ®Google Scholar
• Ulrich-VintherMOsteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strengthCalcif Tissue Int20057628028615812581
   PubMed Web of Science ®Google Scholar
• KonTExpression of osteoprotegerin, receptor activator of NF-_B ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healingJ Bone Miner Res2001161004101411393777
   PubMed Web of Science ®Google Scholar
• GerstenfeldLCComparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healingJ Bone Miner Res20081118 [Epub ahead of print]
   Google Scholar
• KhoslaSAmerican Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• GlowackiJThe deceiving appearances of osteoclastsN Engl J Med20093601808219118309
   PubMed Web of Science ®Google Scholar
• WeinsteinRSGiant osteoclast formation and long-term oral bisphosphonate therapyN Engl J Med20093601536219118304
   PubMed Web of Science ®Google Scholar
• GeusensPPDrug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence – based clinical perspectiveNat Clin Pract Rheumatol20084524024818398411
   PubMedGoogle Scholar
• GoldDTPreference and satisfaction with a 6-monthly subcutaneous injection versus a weekly tablet for treatment of low bone massAbstract M372.
   Google Scholar
• VallealaHTwo year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of diseaseJ Rheumatol20033046847312610803
   PubMed Web of Science ®Google Scholar
• LodderMCEffects of high dose intravenous pamidronate on disease activity and bone metabolism in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled trialJ Rheumatol2003302080208212966622
   PubMed Web of Science ®Google Scholar
• MaksymowychWPBisphosphonates for arthritis: a confusing rationaleJ Rheumatol20033043043412610795
   PubMed Web of Science ®Google Scholar
• JarrettSJPreliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritisArthritis Rheum20065451410141416645968
   PubMed Web of Science ®Google Scholar